

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENT

This announcement is made by Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company has noted that the unusual price and trading volume movements of the shares of the Company (the “**Shares**”) recently. The Company confirms that its business and operation remain unchanged. Having made reasonable enquiries, the Board confirms that, as of the time of this announcement, it is not aware of any information that needs to be disclosed to avoid a false market in the Company’s securities, or any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Guided by the strategy of sustainable growth and global innovation for its second decade of development, the Company has consistently delivered strong results and achieved significant milestones in the past. Looking ahead, the Company believes that 2025 will be a pivotal year for substantial business growth and concrete steps in global innovation.

The Company has established itself as a leading brand in oncology, consistently gaining momentum with an expanding portfolio of synergistic products. Additionally, another key growth driver – the general biomedicine – is poised to unlock substantial opportunities in chronic disease areas, with its highly competitive product portfolio, including mazdutide (GCG/GLP-1), teprotumumab (IGF-1R), and picankibart (IL-23p19), currently under review by the National Medical Products Administration of China for approval.

The Company remains confident in achieving its domestic product revenue target of RMB20 billion by 2027. Alongside rapid business growth, the Company continues to enhance operational efficiency through effective and lean management practices, ensuring a sustainable and healthy operating model.

Meanwhile, in recent years, advancements in the Company’s in-house R&D have paved the way for the global development of a competitive pipeline, including next-generation IO and ADC candidates. The Company plans to expand into more innovative ADCs, bispecific (multi-specific) antibodies, and next-generation autoimmune and cardiovascular and metabolic (CVM) therapies for global development in the future.

The Company remains fully committed to and confident in its growth in both the near and long term and will continue striving toward the vision of becoming a globally premier biopharma company.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
January 16, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as Independent Non-executive Directors.